Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NBIX

Neurocrine Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for NBIX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$6.83

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:02 UTC.

What Neurocrine Biosciences, Inc. does

Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. The company markets four FDA-approved products: INGREZZA for tardive dyskinesia and Huntington's disease chorea, CRENESSITY for congenital adrenal hyperplasia, and elagolix-based treatments for endometriosis and uterine fibroids (commercialized by partner AbbVie). Neurocrine sells INGREZZA through a limited specialty pharmacy network in the U.S.

Summarized from Neurocrine Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$6.83
Return on equity14.71%

Revenue, margins & earnings

FY2021 Net income: $90MFY2021 Operating costs: $1.03B$1.13BFY2021FY2022 Net income: $154MFY2022 Taxes & interest: $94MFY2022 Operating costs: $1.24B$1.49BFY2022FY2023 Net income: $250MFY2023 Operating costs: $1.64B$1.89BFY2023FY2024 Net income: $341MFY2024 Taxes & interest: $229MFY2024 Operating costs: $1.78B$2.36BFY2024FY2025 Net income: $479MFY2025 Taxes & interest: $140MFY2025 Operating costs: $2.24B$2.86BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-15
  • 2026-09-15Chief Financial OfficerSale-2,311$363.3K
  • 2026-09-15DirectorAward14,343—
  • 2026-09-15Chief Commercial OfficerAward6,275—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders.

When did NBIX last file with the SEC?

Neurocrine Biosciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-28. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:02 UTC. This page is also available as JSON at /api/data?ticker=NBIX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NBIX and 5,000+ tickers.

Create a free account — keep NBIX
For your agent
GET /api/data?ticker=NBIX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt